Microbiome CDMO, List Labs, Partners with Genome And Company, to Create Global Microbiome Research, Development, and Manufacturing Powerhouse
Retrieved on:
Tuesday, September 21, 2021
Confidentiality, Business development, Clinical trial, Partnership, Neurological disorder, CDMO, List Biological Laboratories, Therapy, CGMP, Multimedia, LPS, Catalog, Business, Synthetic Genomics (company), CEO, CA, Acquisition, KRX, Research, Drug development, Industry, Republic, Pharmaceutical industry, Antibiotics, Fine chemical
The synergistic relationship with Genome & Company will leverage our shared drive to become the leading global CDMO specialized in the microbiome.
Key Points:
- The synergistic relationship with Genome & Company will leverage our shared drive to become the leading global CDMO specialized in the microbiome.
- This will allow List Labs to generate revenue by continuing to provide world class CDMO services to the open market.
- Stacy Burns-Guydish, Ph.D., President and CEO of List Labs stated, "We are thrilled to strengthen List Lab's capabilities to serve our microbiome CDMO customers.
- The synergistic relationship with Genome & Company will leverage our shared drive to become the leading global CDMO specialized in the microbiome.